drugset / Trial / NCT00926263

A Pharmacokinetic And QT Study Of CP-751,871 In Healthy Subjects

NCT00926263

Phase 1 Terminated 28 enrolled Pfizer
Non-randomizedParallel-groupOpen-labelBasic science

Summary

This study is primarily to evaluate the single dose pharmacokinetics of CP-751,871 and its effect on QT interval prolongation.

Timeline

Start
2009-07
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Figitumumab Monoclonal antibody 10 mg/kg Intravenous
Subject Figitumumab Monoclonal antibody 20 mg/kg Intravenous
Background Moxifloxacin Small molecule

Indications

No indication recorded.